| Michael Jonathan Jaffe, MD | |
|
389 S 900 E, Salt Lake City, UT 84102-2310 | |
| (385) 282-2000 | |
| (385) 282-2001 |
| Full Name | Michael Jonathan Jaffe |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 29 Years |
| Location | 389 S 900 E, Salt Lake City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730119801 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 344455-1205 (Utah) | Secondary |
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | 344455-1205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Interventional Spine And Pain Management | 6204065162 | 9 |
News Archive
A new Regenstrief Institute and Indiana University Center for Aging Research (IUCAR) study provides effective strategies to help hospital systems, physicians and other care providers to overcome end zone hurdles and actually take evidence-based research to the patient's hospital or clinic bedside.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Australian Medical Association (AMA) President, Dr Mukesh Haikerwal, said today that the Australian Government's introduction of chronic disease items to the Medicare Benefits Schedule (MBS) would deliver a double benefit to GPs and their patients.
Nothing less than the development of a passive vaccine against Covid-19 has been undertaken by a team of scientists from Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinkum Erlangen and their partners from the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig and the German Primate Centre in Göttingen.
Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.
› Verified 8 days ago
| Entity Name | Interventional Spine & Pain Management |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609204338 PECOS PAC ID: 6204065162 Enrollment ID: O20140219000458 |
News Archive
A new Regenstrief Institute and Indiana University Center for Aging Research (IUCAR) study provides effective strategies to help hospital systems, physicians and other care providers to overcome end zone hurdles and actually take evidence-based research to the patient's hospital or clinic bedside.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Australian Medical Association (AMA) President, Dr Mukesh Haikerwal, said today that the Australian Government's introduction of chronic disease items to the Medicare Benefits Schedule (MBS) would deliver a double benefit to GPs and their patients.
Nothing less than the development of a passive vaccine against Covid-19 has been undertaken by a team of scientists from Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinkum Erlangen and their partners from the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig and the German Primate Centre in Göttingen.
Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Jonathan Jaffe, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (385) 282-2000 | Michael Jonathan Jaffe, MD 389 S 900 E, Salt Lake City, UT 84102-2310 Ph: (385) 282-2000 |
News Archive
A new Regenstrief Institute and Indiana University Center for Aging Research (IUCAR) study provides effective strategies to help hospital systems, physicians and other care providers to overcome end zone hurdles and actually take evidence-based research to the patient's hospital or clinic bedside.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Australian Medical Association (AMA) President, Dr Mukesh Haikerwal, said today that the Australian Government's introduction of chronic disease items to the Medicare Benefits Schedule (MBS) would deliver a double benefit to GPs and their patients.
Nothing less than the development of a passive vaccine against Covid-19 has been undertaken by a team of scientists from Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinkum Erlangen and their partners from the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig and the German Primate Centre in Göttingen.
Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.
› Verified 8 days ago
James Tran, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: Rehab 85 N Medical Drive Rm 2122, Salt Lake City, UT 84132 Phone: 801-585-2589 | |
Dr. Chase K Hansen, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1121 E Brickyard Rd Apt 1803, Salt Lake City, UT 84106 Phone: 801-309-0848 | |
Michael Tobler, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 6360 S 3000 E Ste 300, Salt Lake City, UT 84121 Phone: 385-900-5094 | |
Dr. Jeffrey G Randle, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1160 E 3900 S, #5000, Salt Lake City, UT 84124 Phone: 801-262-8486 Fax: 801-284-8699 | |
Dr. Michael Matthew Green, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 81 N Mario Capecchi Dr, Department Of Pediatrics, Salt Lake City, UT 84113 Phone: 801-213-7737 Fax: 801-587-7539 | |
Ms. Allison Oki, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr, Univerisity Of Utah, Department Of Pm&r, Salt Lake City, UT 84132 Phone: 801-585-2589 Fax: 801-587-7287 | |
Bradeigh Smithson Godfrey, D.O. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 258 Heritage Ctr, Salt Lake City, UT 84112 Phone: 801-587-1290 |